May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
The Role of Platelet Activating Factor and the Efficacy of Apafant Ophthalmic Solution in Experimental Allergic Conjunctivitis
Author Affiliations & Notes
  • M. Kato
    Research & Development Division, Santen Pharmacerutical, Ikoma, Japan
  • T. Kurose
    Research & Development Division, Santen Pharmacerutical, Ikoma, Japan
  • T. Oda
    Research & Development Division, Santen Pharmacerutical, Ikoma, Japan
  • S. Miyaji
    Research & Development Division, Santen Pharmacerutical, Ikoma, Japan
  • Footnotes
    Commercial Relationships  M. Kato, Santen Pharmacerutical E; T. Kurose, Santen Pharmacerutical E; T. Oda, Santen Pharmacerutical E; S. Miyaji, Santen Pharmacerutical E.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 3755. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Kato, T. Kurose, T. Oda, S. Miyaji; The Role of Platelet Activating Factor and the Efficacy of Apafant Ophthalmic Solution in Experimental Allergic Conjunctivitis . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3755.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To examine relevance of platelet activating factor (PAF) to allergic conjunctivitis and apafant, a potent PAF antagonist, for topical ocular anti-PAF activity in experimental conjunctivitis. Methods: In PAF-induced conjunctivitis models, PAF solution was topically applied to the eyes of guinea pigs. Apafant ophthalmic solution was instilled 15 and 5 min before the challenge. The efficacy was evaluated by determining Evans blue dye extravasation into the ocular tissues, itch-scratching response, and clinical symptoms such as redness and edema. In a passive conjunctival anaphylaxis model, allergic conjunctivitis was elicited by application of ovalbumin solution into the eyes of the guinea pigs that had been passively sensitized with anti-ovalbumin serum. The effect of apafant, which was administered 15 and 5 min before the challenge, was evaluated by determining Evans blue dye extravasation into the ocular tissues. Results: PAF, when applied topically to the eyes of guinea pigs, induction of conjunctival vascular leakage, itch-scratching response, and clinical symptoms such as redness and edema was observed. These symptoms observed in PAF-induced conjunctivitis were well correspondent to those observed in allergic conjunctivitis. Apafant inhibited the responses in a dose-related manner, and the inhibitory effects lasted for about 6 hours duration. In a passive conjunctival anaphylaxis model of guinea pigs, significant inhibition of the allergic response was observed following topical ocular administration of apafant. Conclusions: These results indicate that PAF plays a key role in the pathophysiology of allergic conjunctivitis and apafant is a promising candidate of new anti-allergic eyedrop.

Keywords: pharmacology • conjunctivitis • lipids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×